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Background: Our aim is to provide a state-of-the-art overview of knowledge on sex (biological) and gender
(sociocultural) aspects of Human papillomavirus (HPV) and cervical cancer for educational purposes. Considerable
disparities exist in cervical cancer incidences between different subgroups of women. We provide an outline on the
crucial issues and debates based on the recent literature published in leading gender medicine journals.
Intersectionality was applied in order to help categorise the knowledge.
Methods: Key terms (HPV, cervical cancer) were screened in Gender Medicine, Journal of Women’s Health and
Women & Health from January 2005-June 2012. Additional searches were conducted for topics insufficiently
mentioned, such as HPV vaccination of boys. In total, 71 publications were included (56 original papers, four
reviews, six reports, three commentaries, one editorial and one policy statement).
Results: Research reveals complexity in the way various subgroups of women adhere to cervical screening. Less
educated women, older women, uninsured women, homeless women, migrant women facing language barriers,
women who have sex with women and obese women participate in Pap smears less frequently. A series of barriers
can act to impede decisions to vaccinate against HPV.
Conclusions: Both male and female controlled preventive methods and treatment measures should be developed
in order to tackle HPV infection and different strategies are needed for different subgroups. A substantial discussion
and research on alternative methods of prevention was and is lacking. In future research, sex and gender aspects of
HPV-related diseases of boys and men as well as subgroup differences in HPV risk need to be addressed.
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IntersectionalityIntroduction
Sexually Transmitted Infections (STIs) are a formidable pub-
lic health issue. Many sex and gender differences exist in epi-
demiology, etiology, diagnosis, treatment and consequences
of STIs. There is a clear distinction made between the two –
the term ‘sex’ is reserved for hormonal, chromosomal or any
other features stemming from person’s biology. Gender, on
the other hand, pertains to sociocultural concepts of femin-
inity and masculinity, which can vary between cultures [1].
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reproduction in any medium, provided the orreproductive roles of men and women that cause differences
(such as women’s higher biological vulnerability for STIs),
gender differences occur because women have less power
over sexual situations than men [2]. Gender aspects interact
with biological sex differences in infectious diseases [3].
Human papillomavirus (HPV) infection is one of the
most common STIs, although it is not solely transmitted
sexually, and oncogenic subtypes are associated with cervical
cancer, as well as cancers of the head and neck, anal tumors,
penile cancers, and cancers of the vulva and vagina [4]. In-
fection with High-Risk (HR) HPV strain is necessary but in-
sufficient for cervical cancer to develop. Currently known
co-factors associated with cervical cancer development are
cigarette smoking, alcohol consumption, micronutrientsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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contraception, multiparity, uncircumcised male partner,
low socioeconomic status (SES), infection with HIV/AIDS
or other STIs including herpes simplex and Chlamydia
trachomatis [5,6]. However, other additional factors may
also hinder the immune system in shielding the organism
from these infections. Violence compromises the body’s
ability to counter the infection as well via stress beha-
viours such as smoking or alcohol consumption [7]. How-
ever, the prevalence of stressful life events or self-reported
stress are not always found to be associated with higher
risk for cervical disease [8]. Cervical cancer is also asso-
ciated with different types of violence: childhood sexual
abuse (CSA), intimate partner violence, or forced sexual
experiences [7]. A consequence of CSA is engaging in sex-
ual risky behaviour such as intercourse with casual part-
ners, not using condoms, earlier age of first consensual
intercourse, failing to discuss intercourse in advance, hav-
ing sex with a partner who injects drugs, or having an
HIV positive partner [9]. Studies show that CSA is
reported by twice as many women than men (prevalence
approximately 30% vs. 15%) and more often by subgroups
such as pregnant adolescents, men who have sex with
men, lesbian and bisexual women, women in psychiatric
care, drug users or persons who tested positive for HIV
[9-11].
Developments such as the HPV vaccines and the imple-
mentation of HPV DNA testing for diagnostic purposes
have led to an increase in publications on HPV and heated
public debate. Gender analysis enables us to elucidate dif-
ferent patterns of interaction of gender with race, class,
and other factors [12], which can help us understand how
gender relates to HPV infection, HPV vaccination and
DNA testing.
Men and women cannot be divided into two
homogenous groups, and people’s group memberships
such as gender, age, ethnic background, sexual orientation,
religious affiliation (both assigned and self-identified) re-
define each other. Intersectionality is an approach that
addresses the way gender and other social identities affect
life, and refers to mutually constitutive relationships that
influence each other [13-15]. An intersectionality ap-
proach is based in social justice, and aims to address pro-
cesses of inclusion and exclusion in order to address
issues of marginalised groups [16]. The approach explains
how a single focus on gender, race, or any factor on its
own makes it impossible to examine the manner in which
social forces and locations interact and relate to each other
in order to give shape to the unique mosaic of human
experiences. The elements are fluid and flexible, and a
subgroup at risk lies at the intersection – the place all rele-
vant elements interact. Gender is therefore essential, but
should not be decoupled from other categories, for this
would disable the contextual analysis [15]. In thisliterature review we apply intersectionality in order to
understand the role gender plays in HPV. Thus, we put a
gender lens on HPV and summarise recent publications
from three leading journals in gender medicine.
With an eye for intersectionality, we aim to categorise
recently published knowledge on cervical cancer screen-
ing, HPV DNA testing and HPV vaccination. According
to leading journals in gender medicine, what is state-of-
the-art in regards to gender knowledge about HPV and
cervical cancer?
Materials and methods
The study is funded by the European Union Erasmus
Curriculum Development Project Gender Medicine
EUGiM (2009–2011). State-of-the-art education material
in gender medicine was developed and used during a
postgraduate summer school in Gender Medicine, which
was piloted in Berlin, Germany in September 2010 and
in Sassari, Italy in September 2011.
In order to obtain a good and timely overview in gen-
der and HPV for education purposes, we searched for
recent relevant literature in three renowned and leading
gender medicine journals: Women & Health, Gender
Medicine, and Journal of Women’s Health. We opted for
the choice of these journals due to the fact that relevant
gender-specific publications are often not retrieved by
either conventional searches or the use of filters. More-
over, authors who are insufficiently familiar with the
field often misuse the terms ‘sex’ and ‘gender’; for in-
stance by applying the term ‘gender’ even in cases of
strictly biological differences [17]. The selected journals,
however, cover a broad range of sex and gender-related
aspects and tend to the appropriate use of terminology
and indexing. Women & Health publishes papers on the
physical and psychological health of women, including
environmental factors and prevention, historical over-
views on women’s health and health policy research.
Gender Medicine explicitly publishes papers that use sex
and/or gender approaches in their design. The Journal of
Women’s Health takes a multidisciplinary approach to
health and illness. Hence, a broad overview of recent
research that would include gender aspects of HPV
was anticipated. We searched volumes from January
2005-June 2012 and read title and abstracts. This time-
frame covers studies on the launch and implementation
of the two HPV vaccines and developments in HPV
DNA testing. We included papers if the abstracts men-
tioned HPV, cervical cancer and related issues (risk fac-
tors, behaviours, screening and prevention). Additional
hand searches were performed in order to provide suffi-
cient information on the HPV vaccine debate and the
vaccination of boys. All types of publications were
included. After reading the text, we organised the litera-
ture based on whether it reports on Pap smears, HPV
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cessive referencing, we reduced the number of cited arti-
cles in the text while still focusing on the major factors
presented in the literature.
In total, 71 papers were included in this review, out of
which 56 original papers, four reviews, six reports, three
commentaries, one editorial and one policy statement.
The overview of included papers per year is provided in
Table 1.
Results
The following sections present main findings from the
published research on cervical cancer screening, HPV
DNA testing and HPV vaccines, with an additional focus
on the debate over HPV vaccination and the issue of
vaccinating the boys.
Cervical cancer screening
Differences in HPV prevalence and cervical cancer screen-
ing rates between subgroups of women may exist due to a
mix of patient characteristics, healthcare factors, and pa-
tient and physician attitudes. From 1995–2005 in Europe,
cervical cancer incidence and mortality has declined, al-
though in some countries it increases, such as Lithuania,
Romania, and Bulgaria [6]. Globally, the Pap test is the
principal means of detecting abnormalities, although or-
ganisation of screening programmes, coverage, eligibility
criteria and recommended screening intervals differ. The
Pap smear has become routine and reduced the incidence
and mortality of cervical cancer [46], but cervical cancer
still causes significant morbidity and mortality in develop-
ing countries. For instance in Nigeria, the prevalence of
HR HPV and cytological abnormalities in women is 16.6%
and consistent with other regions in Africa [40]. In Ameri-
can studies, Latinas were less likely to die of the disease
than other groups [23]. Black women diagnosed with loca-
lised cervical cancer less likely had surgery, suggesting less
optimal treatment [47]. In New Zealand, ethnic disparities
in cancer survival are reported as well: Maori women were
diagnosed more often with late stage cervical cancer, andTable 1 Numbers of included papers per each year with refer









total 33had shorter survival, although excess mortality decreased
over the years 1994–2005 [48]. Both SES and ethnic back-
ground are associated with poorer survival.
In many countries, screening programmes are set up
for adult women at certain intervals. Overall, women
who maintain on-schedule Pap tests appear to the gener-
ally healthier than women who do not obtain regular
Pap smears [49]. In the US, women are advised to
undergo annual screening or every 3 years if they had
three consecutive normal Pap tests [20]. Free cancer
screening programmes exist for low-income and unin-
sured women [41]. Different factors and their mutual
interplay appear to play a role in cervical cancer screen-
ing rates. The overview of studies in which a number of
relevant factors were observed, together with the explan-
ation of the manner in which the factors affect the
screening rates, is given in Table 2.
With regards to HPV prevention, screening and treat-
ment, many subgroups of women are underserved such as
women living in rural areas, lesbian women, older women,
or women with low health literacy levels. Cancer screening
programme satisfaction is a critical outcome for the
healthcare system, and for patients with ethnic back-
ground, SES and health status play a role in patient satis-
faction [42]. They often have to be addressed in a
language not sufficiently familiar to them.
The findings on higher frequency of testing in African
American women in the south of the US [41] may be an
indicator that the racial gap in receiving Pap smears in
the US is closing. The fact that non-Hispanic whites ad-
here less to Pap screening might be an outcome of years
long campaigning within minority communities [33]. To
date, experiences of maltreatment were informative of
black people’s skepticism towards healthcare, such as
side effects of HPV vaccine [87]. Within the Asian
American community there are prominent differences,
with the Korean subgroup showing the lowest screening
rates. Japanese American women participate in cervical
cancer screenings considerably less compared to other
cancer screenings [67]. Chinese women in the US haveence numbers in square brackets
HPV DNA testing HPV vaccination
3 [20-22] 0
4 [26-29] 2 [30,31]





1 [82] 4 [83-86]
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Table 2 Various factors influencing the participation rates of women in cervical cancer screening
Factors Main findings
Knowledge – a highly consistent factor contributing to higher participation of women in Pap screening [41,50,66]
SES – low socio-economic status is associated with higher cervical cancer rates, lower Pap smear rates, and
inadequate follow up [41,50,51]
– women age 50+ with higher education are increasingly more up-to-date regarding screening
services with each educational level [32]
Healthcare, access to healthcare, insurance – not having health insurance is associated with not having a recent Pap test in southern US women [41]
– universal healthcare appears to contribute to the reduction of socio-economic status related
differences or differences in screening based on residential location [75]
– an older study however showed that social factors discourage Australia's Indigenous women's use of
and access to health services for screening, diagnosis and treatment of cervical cancer [24]
Age – younger women age 19–26 exhibit more knowledge and participate more in preventive practices
than women age 40–70 [81]
Marital status – participation is higher in married women in Kuwait compared to unmarried women [50]
History of cervical infection, family history – higher prevalence of ever having a Pap test is observed in women with either personal or family
history of cancer [50]
Health expert’s willingness to give
screening recommendation
– physician's recommendation is one of the strongest predictors of having had a Pap test [41]
Lifestyle – smokers and obese persons adhere to Pap testing less frequently [49]
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and lack of general knowledge, however education and
interactions with a Chinese physician largely increased
screening rates [68]. In China, women’s status is inferior
to men’s, and women are more likely to live in poverty.
SES affects Chinese women’s health care seeking behav-
ior for self-reported genitourinary symptoms. Contrary
to conventional wisdom and possibly due to more know-
ledge and awareness of stigma, Chinese women with
high SES may be just as likely or even less likely to seek
treatment for their symptoms [52].
Women who have sex with women (WSW) or lesbian
women have lower screening rates even though HPV is
transmittable between female sex partners and WSW
often do also have (occasionally) sex with male partners
[43,53]. WSW’s risk perceptions for HPV are lower than
expected given the prevalence of abnormal Pap smears
and HPV diagnosis, and thus, characterised by optimistic
bias [43]. WSW may not seek out routine care by physi-
cians, partly because they do not need prescriptions for
contraception. Experiencing the healthcare system as
being heterosexist evolves from the assumed heterosexu-
ality evident in waiting rooms, health forms, and health-
care providers’ assumptions [44]. Fear of discrimination
plays a role in delaying healthcare seeking [69]. In
Canada, lesbian and bisexual women reported poorer
health status on several health measures, but bisexual
women negatively stood out. This group particularly
appears to be not well served in Canadian healthcare
[54], which was also reported in the US [55]. In the UK,
lesbian women are more likely to avoid screening than
heterosexual women, and more likely to have neverattended screening than American lesbian women [18].
In the US, regular cervical cancer screening rates were
equal among women partnering with men, women, or
both [53]. Although a high percentage of lesbian women
engage in sex with women and men, lesbian women may
have a lower cervical cancer risk. However, lesbian women
are more frequently obese and smoke more often, which
may increase their cervical cancer risk [69]. Other sub-
groups of women at risk are presented in the following
Table 3.
HPV DNA testing
Current infections can be measured with highest sensi-
tivity by HPV DNA testing, which can also be combined
with Pap smears for optimising detection of high-grade
cervical intraepithelial neoplasia [82]. Women with a
negative HR HPV DNA test and a negative Pap test can
extend their Pap screening interval [20,26,34]. Protocol
redesign could be focused on those at high risk and be
more cost-effective than existing protocols [27]. How-
ever, a few questions still remain. First, a Pap-plus-HPV
test has higher sensitivity, but lower specificity, and thus
raises the false-positive rate together with the true-
positive rate which may result in over-treatment. Sec-
ondly, the high prevalence of transient infections among
young women is high. And thirdly, a higher number of
women with persistent infections but normal cervices
will be detected. Therefore, a Pap-plus-HPV test may be
more appropriate for women with borderline or mild
Pap abnormalities, because a negative HPV DNA test
could reassure women that their Pap test result is likely
to be aberrant whereas treatment for women with a




- increased HPV prevalence [56]
- both exogenous and endogenous hormones were associated with HPV infection [56]
Women over 55 years
of age
- rarely initiate conversations on sexual matters [25]
- physicians tend to initiate these discussions more with African American women [25]
Incarcerated women - these women (but also incarcerated men), as well as those with a partner being released from prison are at risk due to
their sexual behaviour [19,70]
- more frequent history of abnormal Pap smears, particularly those exposed to violence [76], however they are also more
receptive to prevention [70]
Women with disabilities - may have lower screening rates due to difficulties associated with pelvic examinations[71]
- Canadian women with traumatic spinal cord injury did not have lower screening rates, possibly due to frequent visits to
physicians [71]
- liquid cytology Pap smears are a reasonable alternative for screening this subgroup of women [57]
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[27]. In the United Kingdom, before introduction, HPV
testing was perceived as an added value and would not
negatively affect participation in Pap screening [21].
Informing women of their HPV status has both benefits
and risks. A positive HPV test result may promote safer
sexual practices; empower to adhere to Pap screening
and follow-up; or engage in actions to prevent genital
warts or cervical cancer. On the other hand, negative
psychological side effects can occur such as stigma,
blame and shame [21,28]. Self-collecting vaginal samples
to test for HPV DNA seems feasible and counteracts
barriers to screening attendance such as uncomfortable
or anxiety-provoking pelvic examinations and contact
with providers [22]. Self-collection of an HPV DNA test
was highly acceptable among women because it was easy
to perform, not painful, private, and could be conducted
by the women themselves. However, the highest accept-
ability rates were found in subgroups with the highest
screening rates already. More educational efforts are
needed as many women were concerned whether they
had done the self-collection test correctly [22].
In developing countries, where screening is often inef-
fective or under-utilised if existent at all, screening by fe-
male nurses appeared to be highly acceptable [29]. New
screening methods such as HPV DNA testing, but also
new visual inspection methods, provide opportunities
for low-resource settings, decrease the number of visits
of patients, and can be managed by mid-level healthcare
providers [29]. New genetic technologies may increase
our knowledge not only on pathogen genetics but also
on host genetic factors as regards HPV. Individual gen-
etic susceptibilities may exist with regards to HPV infec-
tion and progress into cervical cancer.
HPV vaccine
A Pap smear detects abnormalities after they occur, thus
pre-cancerous lesions may be missed. Therefore thediscovery of the link between HPV and cervical cancer,
and hence, the possibility of immunisation, enabled pri-
mary prevention. In sharp contrast with routinising Pap
smears, the medical community, policymakers, and the
public showed rapid attention to the HPV vaccines [46].
In 2006, the US Food and Drug Administration (FDA)
approved of a noninfectious recombinant quadrivalent
HPV vaccine (Gardasil) targeting HPV-16 and 18 as well
as HPV-6 and 11 against genital warts for use in girls
and women aged 9–26. In 2008, the second vaccine
(Cervarix) targeting HPV-16 and 18 was marketed. In
the US, the Center for Disease Control (CDC) and the
American Medical Women’s Association recommend
that women are vaccinated against HPV [30]. Young
women are targeted for two reasons. First, immuno-
logical response is strongest in girls aged 10–15, and
secondly, the vaccine is most efficacious in women who
have not yet had sex [5]. The acceptability of the vaccine
is decisive to its implementation [30] and insurance
coverage predicts HPV vaccination, for instance among
young, low-income, urban, predominantly black women.
Also, abnormal Pap test in the past and normative
beliefs that medical providers, parents, and others ap-
prove predicts HPV vaccination as well [58]. A study of
young rural women revealed however that those with a
reported history of an abnormal Pap test or of never
having had a Pap test declined free HPV vaccination
more frequently and vice versa. Higher refusal was also
observed in women engaging in behaviours that increase
the risk of HPV infection, e.g. mutual masturbation [77].
Low awareness of HPV exists among women and men
across different age categories, geographical locations
and racial/ethnic backgrounds [5,59,78]. Even in groups
that demonstrate very high HPV awareness, such as
young women at universities, the knowledge is often mod-
erate. This particularly pertains to Latinas and women
opposed to premarital sex [79]. In a study of the US girls
aged 11–26 receiving their first injection, accurate
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age [83]. Hutson and colleagues [80] explain how the HPV
knowledge gap is present across a broad age spectrum –
in women aged 18–49. In their study of Appalachian
women they describe how the absence of knowledge acts
as a strong barrier to vaccination. The study revealed their
greater concerns over vaccine's side effects rather than
over potential promiscuity effect [80]. Latina mothers’ ac-
ceptability of the HPV vaccine for their children was gen-
erally high, even higher among HPV-positive mothers
[60]. In Singapore however, women had low levels of
awareness and incomplete knowledge of HPV, but accept-
ability of HPV vaccination was high, although acceptability
to vaccinate their children was lower for HPV vaccination
than for other preventable diseases [59].
In a survey study among family practitioners, general
practitioners (GPs), and pediatricians, their agreement
with professional recommendations was the most im-
portant variable determining intention to vaccinate
young female patients [72]. Gynecologists and obstetri-
cians would not offer vaccines mainly because of the
costs and the belief that others should provide vaccines
[61]. A recent CDC report on the US physicians' know-
ledge on the types of cancer that HPV vaccine is effect-
ive against [84] revealed their lower awareness that the
vaccine presents not only cervical, but also vaginal, vul-
var and anal cancer. Only around one quarter of respon-
dents were aware of the effectiveness of the vaccine in
preventing these other types of cancer. Health service
providers working with American Indian/Alaska Native
populations (who have a higher rate of cervical cancer
incidence compared to non-Hispanic white women)
often think that a pregnancy test should precede HPV
vaccination. Also, they are more reluctant to vaccinate
younger patients, which is of concern given the optimal
age when the vaccine exerts maximum benefits [85].
Other barriers, such as costs to parents and difficulties
getting adolescents to primary healthcare providers, are
still unsolved in many countries. Lower vaccine initi-
ation was associated with having parents with low
incomes, having public insurance, and having fewer sex-
ual partners [86].
Debating HPV vaccines
Despite the enthusiastic reception of the HPV vaccines
by women’s health advocates, women at risk, and public
health officials, an intense debate has taken place [35]. A
major concern raised is the vaccines’ effect on screening
practices. Clinicians need to understand the difference
between HPV vaccination to prevent cervical dysplasia
and vaccinations for childhood infectious diseases, as
effectiveness must be evaluated over decades [36]. Anti-
vaccinationists questioned the vaccines’ safety and effi-
cacy [45], and the assumption that there is one age atwhich all girls are negative for HPV fails to account for
the girls who acquired HPV not through sexual contact,
or for the 10-15% of sexually abused girls [36]. US con-
servatives framed the vaccine as ‘the promiscuity vaccine’
and feared that vaccinating preteen girls would sabotage
their message of abstinence from sex before marriage by
‘disinhibition effects’, although such claims were countered
by the CDC. Nevertheless, the debate has influenced pub-
lic opinion about HPV vaccination and the percentage of
parents in favour of mandatory HPV vaccination has
declined. The relationship of the HPV vaccine with the
evocation of a young/teenage women’s sexuality has had a
particular effect which was not seen in other vaccines, for
instance Hepatitis B [45,62].
Others claim that vaccination violates parents’ rights
[5,45]. Intentions to vaccinate seem highest when the
vaccine is presented as of little or no cost to women’s
family and as preventing cancer, and when HPV was not
described as an STI. Costs are thus a realistic barrier for
intention to vaccinate and stigma still follows HPV [63].
In Australia, high levels of acceptance exists towards
vaccination but reservations emerged when women
understood the association between HPV and sexual ac-
tivity [37]. In other countries, the debate is more to be
framed as anti-vaccinationist and questions were raised
about the vaccine’s long-term protection or validity in
the ‘real world’. A systematic review on HPV vaccination
shows that it is highly efficacious in preventing HPV in-
fection and precancerous cervical disease, but long-term
follow up to substantiate reductions in cancer incidence
and mortality is needed in more representative popula-
tions of women [38]. Two RCTs to evaluate the effect of
the quadrivalent vaccine in preventing cancerous lesions
and genital warts showed sustained protection against
low grade (I) lesions attributable to one of the four HPV
types - 6, 11, 16 and 18 - and a substantial reduction of
the disease burden 42 months follow-up [73]. The most
frequently reported adverse effects are pain at the injec-
tion site (78%), bruising or discoloration (17%), swelling
(14%), as well as fainting (15%). These reactions were
reported more in younger girls than the older ones [83].
The vaccine is safe and well-tolerated, although side
effects can only be ruled out at large numbers of vaccines
[5]. A study using the Vaccine Adverse Event Reporting
System to identify cervical cancer and carcinoma in situ
among vaccinated women showed a few cases of cervical
dysplasia and carcinoma in situ [74]. The women may
have been exposed to HPV before vaccination, or to other
HR strains. Moreover, vaccine failures may occur [74].
In Canada, other argumentations were heard. Women’s
health advocates said there were too many unanswered
questions and since cervical cancer in Canada has been
declining, no cervical cancer epidemic exists to warrant
the urgency of a vaccination programme. They warn not
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cancer because most HPV infections clear spontaneously
[39]. Only 2-5% of all women with a cancerous HPV infec-
tion will develop cervix carcinoma within 12–15 years [4].
Boys and HPV vaccination
Little attention is paid to whether boys should be vacci-
nated against HPV as well [64]. Boys are not targeted for
vaccination, which is hardly debated. For instance, in
half of the US newspaper articles on the HPV vaccine
men were not mentioned as possible recipients [31]. But
immunity of the population, or herd immunity, can only
be reached with a gender-inclusive vaccination policy
given the fact that men play an important role as STI
carriers [64]. Another question is why there is so little
knowledge available on male specific HPV-related dis-
ease to begin with. HPV seems associated with testicular
cancer as well as with reduced sperm motility and infer-
tility in men [65]. HPV-related disease such as oropha-
ryngeal cancer, conjunctival squamous cancer, genital
warts and anal and penile cancer does occur among
some groups of men, such as men who have sex with
men (MSM) and HIV positive men [36,65]. Proposals
that boys should receive HPV vaccine to prevent cancer
in women are far more common than claims about pre-
venting penile and anal cancer in men [65].
Discussion
In addition to biological sex differences [3], sociocultural
gender differences, as well as their interaction at many
levels, predict HPV risk and risk behaviour, healthcare
access and screening rates, and consequences. In bio-
medical sex and sociocultural gender research, an inter-
sectional approach is the next step forward [1]; it
provides knowledge on how men and women’s different
positions on aspects such as SES, ethnic background, or
sexual orientation are interdependent and influence STI
risk and health. According to Hankivsky et al. [88], inter-
sectionality directs attention to health conditions that
are more serious for certain groups of women and men.
The relevance of sex and gender cannot be assumed a
priori – other crucial aspects, such as SES, might be
overshadowed by doing so [89]. Using pre-selected cat-
egories (for instance men and women) and treating them
as homogenous and detached from other variables
would be counterproductive, as they redefine each other
[15]. Gaining insight into what happens within and be-
tween different groups takes research one step beyond
subgroup analyses, which assumes categories such as
gender or SES as independent categories. However, un-
equal social relations are incorporated in broad systems
of historical inequalities which intersect, overlap, and
reinforce each other to shape a person’s health status.
Their connections to institutions such as healthcare,education, and law can be the target of intervention ra-
ther than individuals, in order to improve health [90].
We aimed to provide a comprehensive compendium of
HPV-related health issues, diagnostics and prevention
and present this knowledge by applying this approach.
To our knowledge, there are no studies applying gender
analysis coupled with intersectionality approach to this
topic. By targeting the complexity of the intersections
we aimed to shed light on particular subgroups which
should be targeted when dealing with health disparities.
Our study points out several main findings. It shows
that little knowledge of particularly men’s health in HPV
seems available in gender medicine journals, despite the
obvious relationship between gender and STIs and despite
the definition of gender as a relational concept. Existing
knowledge about men seems to focus on MSM, which has
the potential to stigmatise MSM, and leaves men who
have sex with women as well as those who have sex with
men and women out of the picture. However, in every
health condition and even more so in STIs, men and
women’s health are intertwined. Less educated women,
older women, uninsured women, homeless women, mi-
grant women facing language barriers, WSW and obese
women in most societies participate less often in Pap
smears. Certain groups of women who were traditionally
at a higher risk of cervical cancer (e.g. African American
women) appear to be benefiting from community-based
awareness-raising programmes, as a drop in prevalence
can be observed. Other groups at increased risk, like
homeless women, decline free Pap smears nevertheless.
Thus, reasons for lower screening rates among some (sub)
groups are evidently complex. Also, within those groups
known to be at higher risk, for instance older women, we
can observe the positive effect of education on screening
participation. This bares implication for policy develop-
ment and improvements, by helping to narrow down the
focus of intervention to those less educated, therefore
using the resources more effectively.
Our method yielded many papers on HPV and HPV
related topics, mainly due to the launch of the HPV vac-
cine in this time period. Studies on awareness and atti-
tudes in different (sub)groups are still frequent in
journals with a gender focus. Since we chose to incorp-
orate papers from three journals, we may have missed
certain aspects in our overview. The men’s health move-
ment advocates research in men’s health issues and in
the past years several journals have been established in
this field. Future research may focus on their scope in
the field of STIs and HPV.
The European Commission requires attention for gen-
der aspects in health research, and EU-funded researchers
must address sex and gender research in their designs
[90]. This study is but one example of why that ought to
be an imperative. Our overview does provide input for a
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health. First, research on boys and men pertaining to
HPV, both biomedical and gender research, needs to be
accelerated. Furthermore, subgroups of men need atten-
tion, such as men with many sex partners, ageing men
who use sildenafil, and also men who have sex with men
and women. Lastly, research should also aim for a better
understanding of how synergies of social factors contrib-
ute to both men and women’s HPV risk.
Conclusions
As regards HPV prevention, screening, and treatment,
many subgroups of women are underserved such as
women living in rural areas, WSW, older women, or
women with low health literacy levels. Often those at
higher risk of cervical cancer tend to show lower aware-
ness and knowledge regarding the HPV virus and HPV
vaccine. In acquisition and transmission of HPV, gender
relations are essential because of: physical and biological
aspects; structural factors such as access to healthcare;
social differences between men and women and unique
interplays of social factors for each subgroup. Research
on the role of host genetic susceptibilities may yield
more insights on the risk factors in the near future. Vari-
ous measures for preventing acquisition and transmis-
sion of STIs, such as male circumcision, need to be
more seriously considered and with an open mind [91].
Female controlled methods (for instance female con-
doms, microbicides, and diaphragm) can be initiated by
women themselves, which could make them a powerful
resource for women to protect their own health [92,93].
However, these measures to reduce transmission of STIs
are still studied less often and are still undergoing clin-
ical studies [93]. In order to target STIs and HPV infec-
tion, both male and female controlled preventive and
treatment measures need to be developed and different
strategies are needed to reach subgroups of men and
women. An open mind towards different strategies for
prevention of HPV and a conceptualisation of gender as
a relational and intersectional concept in which the
health of men and women impact each other is of major
importance.
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